These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 29533533)

  • 21. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
    Le Blanc K; Frassoni F; Ball L; Locatelli F; Roelofs H; Lewis I; Lanino E; Sundberg B; Bernardo ME; Remberger M; Dini G; Egeler RM; Bacigalupo A; Fibbe W; Ringdén O;
    Lancet; 2008 May; 371(9624):1579-86. PubMed ID: 18468541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases.
    Lim JH; Lee MH; Yi HG; Kim CS; Kim JH; Song SU
    Int J Hematol; 2010 Jul; 92(1):204-7. PubMed ID: 20514533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mesenchymal stem cells for treatment of graft-versus-host disease].
    Najima Y
    Rinsho Ketsueki; 2017; 58(12):2440-2449. PubMed ID: 29332881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
    Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
    Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study.
    Kim N; Min GJ; Im KI; Nam YS; Song Y; Lee JS; Oh EJ; Chung NG; Jeon YW; Lee JW; Cho SG
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
    Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
    Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.
    Macías-Sánchez MDM; Morata-Tarifa C; Cuende N; Cardesa-Gil A; Cuesta-Casas MÁ; Pascual-Cascon MJ; Pascual A; Martín-Calvo C; Jurado M; Perez-Simón JA; Espigado I; Garzón López S; Carmona Sánchez G; Mata-Alcázar-Caballero R; Sánchez-Pernaute R
    Stem Cells Transl Med; 2022 Apr; 11(4):343-355. PubMed ID: 35348788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner.
    Erkers T; Nava S; Yosef J; Ringdén O; Kaipe H
    Stem Cells Dev; 2013 Oct; 22(19):2596-605. PubMed ID: 23701127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells.
    Sadeghi B; Moretti G; Arnberg F; Samén E; Kohein B; Catar R; Kamhieh-Milz J; Geissler S; Moll G; Holmin S; Ringdén O
    Front Immunol; 2019; 10():2685. PubMed ID: 31803191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
    Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation.
    Gao L; Zhang Y; Hu B; Liu J; Kong P; Lou S; Su Y; Yang T; Li H; Liu Y; Zhang C; Gao L; Zhu L; Wen Q; Wang P; Chen X; Zhong J; Zhang X
    J Clin Oncol; 2016 Aug; 34(24):2843-50. PubMed ID: 27400949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.
    Introna M; Lucchini G; Dander E; Galimberti S; Rovelli A; Balduzzi A; Longoni D; Pavan F; Masciocchi F; Algarotti A; Micò C; Grassi A; Deola S; Cavattoni I; Gaipa G; Belotti D; Perseghin P; Parma M; Pogliani E; Golay J; Pedrini O; Capelli C; Cortelazzo S; D'Amico G; Biondi A; Rambaldi A; Biagi E
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):375-81. PubMed ID: 24321746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature.
    Munneke JM; Spruit MJ; Cornelissen AS; van Hoeven V; Voermans C; Hazenberg MD
    Transplantation; 2016 Nov; 100(11):2309-2314. PubMed ID: 26714122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
    Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
    BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.